Pharmaceutical Technology

NOVEMBER 8, 2022

Viatris has signed definitive agreements to acquire Oyster Point Pharma and Famy Life Sciences in a deal totalling nearly $700m-$750m in cash to establish an ophthalmology franchise. A commercial-stage biopharmaceutical firm, Oyster Point discovers, develops and commercialises therapies for treating ophthalmic ailments.

Life Science 148

Life Science Sales Development Drugs 148

XTalks

MARCH 19, 2025

This week, were celebrating a significant milestone: the release of our 200th episode of the Xtalks Life Science Podcast ! We’re excited to continue our journey by bringing you more in-depth conversations with industry leaders, highlighting the innovations and trends that shape the future of life sciences.

Life Science 52

Life Science Branding Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 16, 2023

The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.

Life Science 130

Life Science Genetic Disease Genomics Genome 130

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Development 259

Development Life Science Clinical Trials Clinical Trials 259

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science 315

Life Science Drugs Protein Trials 315

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients. CLDN 18.2).

Development 265

Development Clinical Trials Clinical Trials Life Science 265

XTalks

MARCH 19, 2025

Join us as we celebrate a major milestone the 200th episode of the Xtalks Life Science Podcast! From groundbreaking biotech innovations to exclusive interviews with life science industry innovators and leaders, we’ve covered it all. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 100

Life Science Clinical Development Development Research 100

Cloudbyz

NOVEMBER 22, 2024

We are deeply honored to be recognized in Everest Group’s PEAK Matrix® for Life Sciences CTMS solutions,” said Dinesh Kashyap, CEO and Founder of Cloudbyz. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”

Life Science 52

Life Science Clinical Trials Clinical Trials Compliance 52

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 257

Gene Therapy Gene Development Manufacturing 257

XTalks

JANUARY 31, 2024

This episode features an interview with Punit Dhillon, Chairman & CEO of Skye Bioscience , a pharmaceutical company developing proprietary molecules to treat diseases involving inflammatory, fibrotic and metabolic conditions. Skye Bioscience is at the forefront of exploring the endocannabinoid system for drug development.

Life Science 116

Life Science Development Drugs Medicine 116

Bio Pharma Dive

AUGUST 17, 2021

Bain Capital's latest life sciences fund, its third, is another example of private equity's growing interest in drug development.

Life Science 263

Life Science Development Drugs 263

pharmaphorum

JANUARY 25, 2024

Discover the role of GenAI in life sciences in 2024. Explore how artificial intelligence and machine learning techniques like GenAI are revolutionising drug development, diagnostics, and research. Learn how industry leaders, including Google, are leveraging GenAI to advance healthcare and enhance patient outcomes.

Life Science 115

Life Science Development Drugs Research 115

Pharmaceutical Technology

SEPTEMBER 23, 2022

RA Capital Management led the financing round, which also saw participation from Bain Capital Life Sciences and BB Biotech. The post Rivus raises $132m to advance clinical development of obesity treatment appeared first on Pharmaceutical Technology.

Clinical Development 242

Clinical Development Development Life Science Trials 242

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Bio Pharma Dive

NOVEMBER 7, 2022

The generics company is acquiring Oyster Point Pharma and the privately held Famy Life Sciences in a move aimed at creating an ophthalmology business.

Life Science 210

Life Science Development Drugs 210

Pharmaceutical Technology

SEPTEMBER 9, 2024

RESCAP is under clinical development by Alloksys Life Sciences and currently in Phase II for Burns.

Life Science 100

Life Science Clinical Development Development 100

Pharmaceutical Technology

JUNE 2, 2023

Anavex Life Sciences has secured new US intellectual property compositions patent for its ANAVEX 2-73 (blarcamesine). We are extremely pleased with the continued development of the patent portfolio for ANAVEX 2-73 (blarcamesine) which demonstrates our continued commitment to protecting all aspects of the Anavex product portfolio.”

Life Science 130

Life Science Clinical Trials Clinical Trials Trials 130

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

XTalks

FEBRUARY 15, 2024

In the life sciences, countless Black scientists, researchers and medical professionals have made groundbreaking discoveries that have significantly advanced our understanding of biology and medicine. Drew’s work laid the groundwork for the American Red Cross Blood Bank and other blood donation programs worldwide.

Life Science 115

Life Science Scientist Research Protein 115

Pharmaceutical Technology

JANUARY 5, 2025

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

Life Science 100

Life Science Clinical Development Development 100

Pharmaceutical Technology

FEBRUARY 15, 2023

JSR Life Sciences’ business unit Similis Bio is planning to collaborate with Novel351k for the development of three biosimilar programmes targeting cancer and autoimmune diseases. Under the terms of the initial deal, Similis Bio will handle the development of cell lines, analytics, process development, and cGMP production.

Development 148

Development Life Science Manufacturing Clinical Trials 148

XTalks

FEBRUARY 21, 2024

This episode features an interview with Amir Reichman, CEO of Scinai Immunotherapeutics , a biopharma company focused on developing cutting-edge biological treatments within the inflammation and immunology (I&I) sector, with a primary focus on addressing autoimmune and infectious diseases.

Life Science 105

Life Science Development Antibody Vaccine 105

XTalks

MARCH 20, 2024

In this featured episode of Xtalks People in Life Sciences, Ayesha spoke with Ashish Jain, Senior Director of Clinical Safety and Pharmacovigilance (PV) at Curis , a pioneering biotech company specializing in cutting-edge cancer therapies. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 113

Life Science Development Drugs 113

Pharmaceutical Technology

APRIL 5, 2024

Caris Life Sciences has entered a collaboration with Merck KGaA for the development of antibody-drug conjugates (ADCs) for cancer.

Development 130

Development Life Science Antibody Drugs 130

XTalks

FEBRUARY 14, 2024

This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, Chief Financial Officer at OncoC4 , a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 119

Life Science DNA Production Clinical Trials 119

XTalks

SEPTEMBER 6, 2023

David Young, founder and President R&D at Processa Pharmaceuticals, a clinical-stage pharmaceutical company developing personalized approaches to cancer treatments with a focus on next generation chemotherapy drugs with improved safety and efficacy. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 116

Life Science Drugs Development Research 116

pharmaphorum

MARCH 6, 2025

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development.

Life Science 100

Life Science Development Drugs 100

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. The trial will also lay the ground for additional trials for acute and long Covid in the US.

Development 163

Development Life Science Immune Response Trials 163

Drug Discovery World podcast

MARCH 20, 2025

This is the latest episode of the free DDW narrated podcast, titled Critical tools that support drug discovery and development, which covers two articles written for DDW Volume 24 Issue 3, Summer 2023.They and Big data: Charting a new path to drug discovery and development .

Development 52

Development Life Science Drugs Big Data 52

XTalks

JANUARY 17, 2024

Monogram is focused on developing patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. Ben is an engineer by training and before joining Monogram, he served as the Director of Business Development at Pro-Dex, an OEM manufacturer of Orthopedic Robotic End-Effectors.

Life Science 115

Life Science Engineer Business Development Development 115

Pharmaceutical Technology

MARCH 2, 2023

The growth in sales was driven by all regions and business sectors, particularly Life Science. resulted primarily from the development of the US dollar and the Chinese renminbi. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

XTalks

NOVEMBER 1, 2023

Stephanie Manson Brown, VP & Head of Clinical Development & Scientific Innovation of R&D at Allergan Aesthetics at AbbVie. Dr. Manson Brown’s Clinical Development and Scientific Innovation team are responsible for global clinical trial development strategy for the Aesthetic Medicine portfolio, covering pharmaceuticals and device.

Life Science 105

Life Science Clinical Trials Clinical Trials Clinical Development 105

XTalks

APRIL 3, 2024

This episode features an interview with Bruce Culleton, MD, CEO, ProKidney , a late clinical-stage biotech company focused on the development of a pioneering cell therapy candidate that aims to transform the treatment landscape for chronic kidney disease. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 105

Life Science Clinical Trials Clinical Trials Manufacturing 105

XTalks

OCTOBER 24, 2024

Panagos, an industry veteran with extensive experience in the healthcare and life sciences sector, takes over from Colin Shannon, who served as CEO for one year following the company’s acquisition by a consortium of private equity firms. Shannon has now been appointed Executive Chairman of Syneos.

Life Science 105

Life Science Clinical Development Development Clinical Research 105

XTalks

OCTOBER 31, 2024

Dr. Perkins has also led the development and implementation of innovative digital educational outreach campaigns for primary care physicians. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Prior to joining Bayer, Dr. Perkins held leadership roles with Novartis and AstraZeneca.

Life Science 52

Life Science Cardiology Trials Development 52

XTalks

APRIL 17, 2024

In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics , a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 111

Life Science Production Development 111

XTalks

MARCH 27, 2024

Dr. Perkins has also led the development and implementation of innovative digital educational outreach campaigns for primary care physicians. In previous roles, Dr. Perkins helped build and develop medical teams at Novartis and AstraZeneca. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 105

Life Science Development Trials 105